FY2025 EPS Estimates for Acasti Pharma Inc. Increased by Analyst (NASDAQ:ACST)

Acasti Pharma Inc. (NASDAQ:ACST) – Research analysts at HC Wainwright upped their FY2025 earnings per share (EPS) estimates for Acasti Pharma in a report issued on Monday, July 1st. HC Wainwright analyst O. Livnat now anticipates that the biopharmaceutical company will post earnings of ($1.14) per share for the year, up from their prior forecast of ($1.29). The consensus estimate for Acasti Pharma’s current full-year earnings is ($1.29) per share. HC Wainwright also issued estimates for Acasti Pharma’s FY2026 earnings at ($0.76) EPS and FY2027 earnings at ($0.83) EPS.

Acasti Pharma (NASDAQ:ACST) last released its quarterly earnings results on Friday, June 21st. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.48) by $0.30.

Acasti Pharma Stock Performance

ACST opened at $2.85 on Wednesday. The company has a market cap of $26.79 million, a PE ratio of -1.98 and a beta of 1.55. The stock has a 50-day moving average of $2.93 and a 200-day moving average of $2.95. Acasti Pharma has a 52-week low of $1.72 and a 52-week high of $3.84.

Acasti Pharma Company Profile

Acasti Pharma Inc engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia.